Binusha Moitheennazima, MD
Pulmonary Disease · Nacogdoches, TXNPI 1760658330
Payments from drug & device makers
Across 506 payments — averaging $30.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- GSK$2K
- Boehringer Ingelheim$934
- Mylan Specialty L.p.$566
- Sanofi$558
- Jazz Pharmaceuticals Inc.$357
- plus $3K from 31 others
What the payments were for
- Consulting fees$5,07633%
- Food & beverage$10,24466%
- Education$1691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 109 | $7,797 |
| GSK | 123 | $2,170 |
| Boehringer Ingelheim | 45 | $934 |
| Mylan Specialty L.p. | 29 | $566 |
| Sanofi | 24 | $558 |
| Jazz Pharmaceuticals Inc. | 13 | $357 |
| Verona Pharma, Inc. | 29 | $311 |
| Sunovion Pharmaceuticals Inc. | 16 | $267 |
| Regeneron Healthcare Solutions, Inc. | 11 | $242 |
| Amgen | 6 | $226 |
| Philips North America LLC | 13 | $216 |
| Paratek Pharmaceuticals, Inc. | 7 | $214 |
| Actelion Pharmaceuticals US, Inc. | 12 | $152 |
| Genentech USA, Inc. | 7 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $120 |
| Pfizer | 6 | $114 |
| Merck | 5 | $101 |
| Harmony Biosciences LLC | 4 | $99 |
| Viatris Specialty LLC | 4 | $98 |
| Inspire Medical Systems, Inc. | 2 | $92 |
| Insmed, Inc. | 4 | $88 |
| ANI Pharmaceuticals, Inc. | 3 | $73 |
| Baxter Healthcare | 4 | $68 |
| Sanofi-aventis U.S. LLC | 4 | $68 |
| Pulmonx Corporation | 2 | $61 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $54 |
| Advanced Respiratory, Inc | 3 | $51 |
| Electromed, Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $41 |
| Vapotherm Inc | 2 | $30 |
| Vifor Pharma, Inc. | 1 | $28 |
| Johnson & Johnson | 2 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Kaleo, Inc. | 1 | $19 |
| Resmed Corp | 1 | $16 |
| Bayer | 1 | $15 |
| United Therapeutics Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,489 in reported general payments places this provider in the 75th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 30 | $416,002 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 540 | $385,465 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 227 | $166,902 |
| ZemairaAlpha-1-Proteinase Inhibitor | 16 | $142,927 |
| Breo ElliptaFluticasone/Vilanterol | 227 | $104,531 |
| IngrezzaValbenazine Tosylate | 22 | $104,342 |
| EliquisApixaban | 293 | $103,376 |
| Advair HfaFluticasone Propion/Salmeterol | 284 | $100,404 |
| Fasenra PenBenralizumab | 17 | $94,051 |
| SymbicortBudesonide/Formoterol Fumarate | 274 | $83,995 |
| Spiriva RespimatTiotropium Bromide | 101 | $61,909 |
| NucalaMepolizumab | 14 | $54,893 |
| Spiriva HandihalerTiotropium Bromide | 55 | $39,110 |
| XareltoRivaroxaban | 80 | $33,441 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $31,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $2,170 | $610,373945 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $934 | $516,115196 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Farxiga | $7,797 | $274,985566 claims |
| PfizerEliquis | $114 | $103,376293 claims |
| Johnson & JohnsonXarelto | $27 | $33,44180 claims |
| MerckJanuvia, Dulera | $101 | $30,986106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Nacogdoches
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.